Clinical studies showed that ESR1 mutations that promote ligand-independent activation (e.g., Y537S, D538G) occur predominantly in metastatic or advanced breast cancer patients who were previously treated with estrogen deprivation therapy, especially aromatase inhibitors. This evidence concerns the gene CYP19A1 and breast cancer.